Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy.

Literature DB >> 2405924

Treatment strategies in acute myeloid leukemia (AML). A. First-line chemotherapy.

Abstract

Chemotherapy remains the backbone of treatment in AML. Of all adult patients 65% go into remission and have a chance of longer survival and of even being cured. Among the responders, 25% can be cured by intensive and long-term chemotherapy. Since the effect of chemotherapy appears not to be limited to a special period of time, its antileukemic and curative potential could be further exploited by multiple-step chemotherapy combining double induction, intensified consolidation and long-term maintenance. Improved antimicrobial treatment and the use of hematopoietic growth factors may help making multiple-step chemotherapy practicable, thereby increasing the cure rate in AML.

Entities: Disease Species

Mesh：

Year: 1990 PMID： 2405924 DOI： 10.1007/bf01720509

Source DB: PubMed Journal: Blut ISSN： 0006-5242

23 in total

1. Improved treatment results in the myelocytic subtypes FAB M1-M4 but not in FAB M5 after intensification of induction therapy: results of the German childhood AML studies BFM-78 and BFM-83.

Authors: J Ritter; U Creutzig; G Schellong
Journal: Haematol Blood Transfus Date: 1990

2. Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.

Authors: T Büchner; W Hiddemann; S Blasius; P Koch; G Maschmeyer; C Tirier; H Sodomann; R Kuse; E Thiel; W D Ludwig
Journal: Haematol Blood Transfus Date: 1990

3. A randomized comparison of postremission therapy in acute myelogenous leukemia: a Southeastern Cancer Study Group trial.

Authors: W R Vogler; E F Winton; D S Gordon; M R Raney; B Go; L Meyer
Journal: Blood Date: 1984-05 Impact factor: 22.113

4. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

Authors: B Löwenberg; R Zittoun; H Kerkhofs; U Jehn; J Abels; L Debusscher; C Cauchie; M Peetermans; G Solbu; S Suciu
Journal: J Clin Oncol Date: 1989-09 Impact factor: 44.544

Review 5. Acute myeloblastic leukaemia in the elderly.

Authors: J A Copplestone; A G Prentice
Journal: Leuk Res Date: 1988 Impact factor: 3.156

6. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.

Authors: J Yates; O Glidewell; P Wiernik; M R Cooper; D Steinberg; H Dosik; R Levy; C Hoagland; P Henry; A Gottlieb; C Cornell; J Berenberg; J L Hutchison; P Raich; N Nissen; R R Ellison; R Frelick; G W James; G Falkson; R T Silver; F Haurani; M Green; E Henderson; L Leone; J F Holland
Journal: Blood Date: 1982-08 Impact factor: 22.113

7. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study.

Authors: H Preisler; R B Davis; J Kirshner; E Dupre; F Richards; H C Hoagland; S Kopel; R N Levy; R Carey; P Schulman
Journal: Blood Date: 1987-05 Impact factor: 22.113

8. High-dose cytosine arabinoside and mitoxantrone: a highly effective regimen in refractory acute myeloid leukemia.

Authors: W Hiddemann; H Kreutzmann; K Straif; W D Ludwig; R Mertelsmann; R Donhuijsen-Ant; E Lengfelder; Z Arlin; T Büchner
Journal: Blood Date: 1987-03 Impact factor: 22.113

9. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results.

Authors: S N Wolff; R H Herzig; J W Fay; G L Phillips; H M Lazarus; J M Flexner; R S Stein; J P Greer; B Cooper; G P Herzig
Journal: J Clin Oncol Date: 1989-09 Impact factor: 44.544

10. Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78.

Authors: U Creutzig; J Ritter; H Riehm; H J Langermann; G Henze; H Kabisch; D Niethammer; H Jürgens; B Stollmann; U Lasson
Journal: Blood Date: 1985-02 Impact factor: 22.113

8 in total

1. Bone marrow transplantation or chemotherapy as post-remission treatment of adult acute myelogenous leukemia.

Authors: R Willemze; W E Fibbe; J C Kluin-Nelemans; J H Falkenburg; D J Richel; W G Peters; G J den Ottolander; A Brand; F E Zwaan
Journal: Ann Hematol Date: 1991 Feb-Mar Impact factor: 3.673

Review 2. [Therapy of infections in patients with acute leukemia].

Authors: W Hiddemann; G Maschmeyer; H Link; M Helmerking; D Adam
Journal: Med Klin (Munich) Date: 1997-07-15

Review 3. Cytosine arabinoside in the treatment of acute myeloid leukemia: the role and place of high-dose regimens.

Authors: W Hiddemann
Journal: Ann Hematol Date: 1991-04 Impact factor: 3.673

4. Recombinant human interferons alpha, beta and gamma reduce the antiproliferative action of cytarabine in K562 human myeloid leukaemia clonogenic cells.

Authors: H R Maurer; H T Hassan; C Tsiriyotis; D A Spandidos
Journal: J Cancer Res Clin Oncol Date: 1992 Impact factor: 4.553